Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2017Website:
http://www.kalarx.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 75 min agoDividend
Analysts recommendations
Institutional Ownership
KALA Latest News
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Kala Pharmaceuticals?
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
What sector is Kala Pharmaceuticals in?
Kala Pharmaceuticals is in the Healthcare sector
What industry is Kala Pharmaceuticals in?
Kala Pharmaceuticals is in the Biotechnology industry
What country is Kala Pharmaceuticals from?
Kala Pharmaceuticals is headquartered in United States
When did Kala Pharmaceuticals go public?
Kala Pharmaceuticals initial public offering (IPO) was on 20 July 2017
What is Kala Pharmaceuticals website?
https://www.kalarx.com
Is Kala Pharmaceuticals in the S&P 500?
No, Kala Pharmaceuticals is not included in the S&P 500 index
Is Kala Pharmaceuticals in the NASDAQ 100?
No, Kala Pharmaceuticals is not included in the NASDAQ 100 index
Is Kala Pharmaceuticals in the Dow Jones?
No, Kala Pharmaceuticals is not included in the Dow Jones index
When was Kala Pharmaceuticals the previous earnings report?
No data
When does Kala Pharmaceuticals earnings report?
The next expected earnings date for Kala Pharmaceuticals is 13 November 2024